Nesivine Pédiatrie Sine Conservans (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nesivine Pédiatrie Sine Conservans, is an alpha‑adrenergic agonist presented as a nasal solution for nasal use. It relieves nasal congestion associated with rhinitis in children and adolescents. GNH USA supplies Nesivine Pédiatrie Sine Conservans as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline acts on the nasal mucosa to reduce swelling and improve airflow in several upper‑respiratory conditions.

Nasal congestion: provides rapid decongestion by shrinking swollen nasal vessels. Allergic rhinitis: alleviates blockage caused by allergic inflammation. Non‑allergic rhinitis: reduces edema and improves breathing in irritant‑induced rhinitis.

Oxymetazoline is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Nasal burning or stinging sensation. - Mild headache. - Dryness of the nasal mucosa. - Sneezing. - Temporary taste alteration.

Serious or Rare Side Effects: - Persistent hypertension or elevated blood pressure. - Cardiac palpitations or arrhythmia. - Severe nasal irritation or ulceration. - Allergic reactions such as rash, itching, or swelling.

Before using Oxymetazoline, consider the following safety measures.

Avoid prolonged use: limit application to no more than three consecutive days to prevent rebound congestion. Pregnancy and breastfeeding: consult a healthcare professional, as safety data are limited. Cardiovascular disease: use with caution in patients with hypertension or heart conditions. Drug interactions: review concomitant medications, especially other vasoconstrictors. Children under recommended age: follow age‑specific guidelines provided by the prescriber. Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline may interact with certain systemic agents, altering its safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may potentiate vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: possible additive cardiovascular effects. - Other nasal decongestants: increased risk of rebound congestion. - Antihypertensive drugs: may reduce their efficacy. - Sympathomimetic agents: potential for additive pressor response.